Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| |
| Authors: | Melanie J. Davies David A. D’Alessio Judith Fradkin Walter N. Kernan Chantal Mathieu Geltrude Mingrone Peter Rossing Apostolos Tsapas Deborah J. Wexler John B. Buse |
| |
| Affiliation: | 1.Diabetes Research Centre,University of Leicester,Leicester,UK;2.Leicester Diabetes Centre,Leicester General Hospital,Leicester,,UK;3.Department of Medicine,Duke University School of Medicine,Durham,USA;4.National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,USA;5.Department of Medicine,Yale School of Medicine,New Haven,USA;6.Clinical and Experimental Endocrinology,UZ Gasthuisberg, KU Leuven,Leuven,Belgium;7.Department of Internal Medicine,Catholic University,Rome,Italy;8.Diabetes and Nutritional Sciences,King’s College London,London,UK;9.Steno Diabetes Center Copenhagen,Gentofte,Denmark;10.University of Copenhagen,Copenhagen,Denmark;11.Second Medical Department,Aristotle University Thessaloniki,Thessaloniki,Greece;12.Department of Medicine and Diabetes Unit,Massachusetts General Hospital,Boston,USA;13.Harvard Medical School,Boston,USA;14.Department of Medicine,University of North Carolina School of Medicine,Chapel Hill,USA |
| |
| Abstract: | ![]()
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium–glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
